Logo

Optimization of HER2-based and cell-based ELISA for detection of trastuzumab biosimilar

Author(s):
Maryam AhmadzadehMaryam Ahmadzadeh, Farzaneh FarshdariFarzaneh Farshdari, Leila NematollahiLeila Nematollahi, Shayan MalekniaShayan Maleknia, Elham MohitElham Mohit,*

Koomesh:Vol. 22, issue 2; 341-350
Published online:Sep 02, 2020
Article type:Research Article
Received:Jul 01, 2019
Accepted:Sep 02, 2019
How to Cite:Maryam AhmadzadehFarzaneh FarshdariLeila NematollahiShayan MalekniaElham MohitOptimization of HER2-based and cell-based ELISA for detection of trastuzumab biosimilar.koomesh.22(2):e153187.

Abstract

References

  • 1.
    Thongsuksai P, Chongsuvivatwong V, Sriplung H. Delay in breast cancer care: a study in Thai women. Med Care 2000; 38: 108-114.
  • 2.
    Taslimi Y, Zahedifard F, Habibzadeh S, Taheri T, Abbaspour H, Sadeghipour A, et al. Antitumor effect of IP-10 by using two different approaches: live delivery system and gene therapy. J Breast Cancer 2016; 19: 34-44.
  • 3.
    Semnani V, Farhidzadeh E, Mirmohammadkhani M, Ghahremanfard F. Investigation of blood levels of vitamin D in women with breast cancer and its correlation with prognostic markers. Koomesh 2017; 735-741. (Persian).
  • 4.
    Parise CA, Bauer KR, Brown MM, Caggiano V. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. Breast J 2009; 15: 593-602.
  • 5.
    Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2012; 9: 16-32.
  • 6.
    Ahmadi A, Mohagheghi MA, Fazeli MS, Nahavandian B, Bashardoost N, Jarahi AM, Gharipoor M. HESA-A: new treatment for breast cancer and choroidal metastasis. Med Sci Monit 2005; 11: CR300-CR303.
  • 7.
    Murphy CG, Modi S. HER2 breast cancer therapies: a review. Biologics 2009; 3: 289-301.
  • 8.
    Kauraniemi P, Kallioniemi A. Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer. Endocr Relat Cancer 2006; 13: 39-49.
  • 9.
    Foroumadi S, Rajabi bazl M, Hosseini H, Rajabi S, Shahidi S, Daraei A, Toofani Milani A. Expression and characterization of recombinant human epidermal growth factor receptor antigene (HER-2) as an indicator of breast cancer in yeast fermented systems. Koomesh 2016; 18: 110-116. (Persian).
  • 10.
    Tai W, Mahato R, Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. J Control Release 2010; 146: 264-275.
  • 11.
    Mohit E, Hashemi A, Allahyari M. Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines. Expert Rev Clin Immunol 2014; 10: 927-961.
  • 12.
    Surez I, Salmern-Garca A, Cabeza J, Capitn-Vallvey LF, Navas N. Development and use of specific ELISA methods for quantifying the biological activity of bevacizumab, cetuximab and trastuzumab in stability studies. J Chromatogr B Analyt Technol Biomed Life Sci 2016; 1032: 155-164.
  • 13.
    Cheng W, Allen T. The use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatment. Expert Opin Drug Deliv 2010; 7: 461-478.
  • 14.
    Damen CW, de Groot ER, Heij M, Boss DS, Schellens JH, Rosing H, et al. Development and validation of an enzyme-linked immunosorbent assay for the quantification of trastuzumab in human serum and plasma. Anal Biochem 2009; 391: 114-120.
  • 15.
    Steinitz M. Quantitation of the blocking effect of tween 20 and bovine serum albumin in ELISA microwells. Anal Biochem 2000; 282: 232-238.
  • 16.
    Sentandreu MA, Aubry L, Toldr F, Ouali A. Blocking agents for ELISA quantification of compounds coming from bovine muscle crude extracts. Eur Food Res Technol 2007; 224: 623-628.
  • 17.
    Khan MS, Pande T, van de Ven TG. Qualitative and quantitative detection of T7 bacteriophages using paper based sandwich ELISA. Colloids Surf B Biointerfaces 2015; 132: 264-270.
  • 18.
    Crowther R. The ELISA Guidebook. ed. Humana Press; 2009; 88-97.
  • 19.
    Mosayebi G, Abtahi H, Ghazavi A, Zareinfar N, Khaki M, Payani MA. Design of enzyme-linked immunosorbent assay method for detection of anti-streptolysin-O antibodies on base of recombinant streptolysin-O. Koomesh 2012; 13: 362-368. (Persian).
  • 20.
    Pterfi Z, Kocsis B. Comparison of blocking agents for an ELISA for LPS. J Immunoassay 2000; 21: 341-354.
  • 21.
    Coory M, Thornton K. Randomised clinical endpoint studies for trastuzumab biosimilars: a systematic review. Breast Cancer Res Treat 2019; 1: 17-25.
  • 22.
    Holbech H, Andersen L, Petersen GI, Korsgaard B, Pedersen KL, Bjerregaard P. Development of an ELISA for vitellogenin in whole body homogenate of zebrafish (Danio rerio). Comp Biochem Physiol C Toxicol Pharmacol 2001; 130: 119-131.
  • 23.
    Dixit CK, Vashist SK, MacCraith BD, O'kennedy R. Multisubstrate-compatible ELISA procedures for rapid and high-sensitivity immunoassays. Nat Protoc 2011; 6: 439-445.
  • 24.
    Kaur R, Dikshit KL, Raje M. Optimization of immunogold labeling TEM: an ELISA-based method for evaluation of blocking agents for quantitative detection of antigen. J Histochem Cytochem 2002; 50: 863-873.
  • 25.
    Khodashenas S, Khalili S, Moghadam MF. A cell ELISA based method for exosome detection in diagnostic and therapeutic applications. Biotechnol Lett 2019; 41: 523-531.
  • 26.
    Meysami P, Rezaei F, Marashi SM, Amiri MM, Bakker E, Mokhtari-Azad T. Antitumor effects of a recombinant baculovirus displaying anti-HER2 scFv expressing Apoptin in HER2 positive SK-BR-3 breast cancer cells. Future Virol 2019; 14: 139-152.
  • 27.
    Maple L, Lathrop R, Bozich S, Harman W, Tacey R, Kelley M, Danilkovitch-Miagkova A. Development and validation of ELISA for Herceptin detection in human serum. J Immunol Methods 2004; 295: 169-182.
  • 28.
    Tan WB, Jiang S, Zhang Y. Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference. Biomaterials 2007; 28: 1565-1571.
  • 29.
    Alric C, Herv-Aubert K, Aubrey N, Melouk S, Lajoie L, Mme W, et al. Targeting HER2-breast tumors with scFv-decorated bimodal nanoprobes. J Nanobiotechnology 2018; 16: 18.
  • 30.
    Lattrich C, Juhasz-Boess I, Ortmann O, Treeck O. Detection of an elevated HER2 expression in MCF-7 breast cancer cells overexpressing estrogen receptor 1. Oncol Rep 2008; 19: 811-817.
  • 31.
    Huang R, Wang Q, Zhang X, Zhu J, Sun B. Trastuzumab-cisplatin conjugates for targeted delivery of cisplatin to HER2-overexpressing cancer cells. Biomed Pharmacother 2015; 72: 17-23.##https://doi.org/10.1016/j.biopha.2015.03.004.
  • 32.
    Sarial S, Sonboli R, Maleknia S, Ashori F, Rezaeiravesh S, Nouri SZ, et al. Development, optimization and validation of a sandwich ELISA for detection of recombinant human factor VII. South Asian J Exper Biol 2015; 5: 26-31.##.
comments

Leave a comment here

Share on
Metrics

Purchasing Reprints

  • Copyright Clearance Center (CCC) handles bulk orders for article reprints for Brieflands. To place an order for reprints, please click here (   https://www.copyright.com/landing/reprintsinquiryform/ ). Clicking this link will bring you to a CCC request form where you can provide the details of your order. Once complete, please click the ‘Submit Request’ button and CCC’s Reprints Services team will generate a quote for your review.
Search Relations

Author(s):

Related Articles